Axsome to Present Symbravo Data at American Headache Society Meeting
Axsome Therapeutics announced that data from the SYMBRAVO (meloxicam and rizatriptan) clinical program will be presented at the 67th...
Jon Napitupulu
Neurona Doses First Patient in NRTX-1001 Cell Therapy Trial
Neurona Therapeutics has dosed the first patient in a Phase 1/2 clinical trial of NRTX-1001, a regenerative cell therapy,...
Eolo Pharma’s Novel Obesity Drug Activates Energy-Burning Pathway
Eolo Pharma announced positive results from its first-in-human study of SANA, a novel drug targeting creatine-dependent thermogenesis for obesity...
NorthStrive Biosciences Initiates Phase II of AI-Powered Therapy Collaboration
Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., has initiated Phase II of its AI drug development program with...
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy
The FDA granted Orphan Drug Designation to Capricor Therapeutics’ Deramiocel for treating Becker Muscular Dystrophy (BMD). This designation expands...
Ventyx Biosciences Positive Top-Line Data for Parkinson’s
Ventyx Biosciences announced positive top-line results from its Phase 2a study of VTX3232, an oral NLRP3 inhibitor, in patients...
Centessa Announces IND Clearance for Novel OX2R Agonist, ORX142
Centessa Pharmaceuticals has received FDA clearance to begin a Phase 1 clinical trial of ORX142, a new OX2R agonist,...
MBX Biosciences Announces IND Submission of MBX 4291 for Obesity Treatment
MBX Biosciences has submitted an Investigational New Drug (IND) application to the FDA for MBX 4291, a long-acting GLP-1/GIP...
Micron and Emory Launch Trial of Next-Gen Rotavirus Vaccine
Emory University and Micron Biomedical have launched the first clinical trial of a rotavirus vaccine, CC24, delivered via dissolvable...
Ocugen Announces FDA Clearance of Ocu410ST for Stargardt Disease
Ocugen, a gene therapy company, received FDA clearance to begin a Phase 2/3 trial for OCU410ST, a modifier gene...